• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025.

    Fourth Quarter and Full Year Recent Business Updates

    • Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the period
    • Raised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asset value ("NAV")/share accretive basis
    • Repurchased $3.4 million of common stock in 2026, funded primarily through the sale of SOL, while NAV/share accretive to do so
    • Adopted share repurchase program, initiating share repurchases totaling $3.4 million to-date in 2026
    • The Company continues to evaluate a broad range of capital actions, including equity and debt financings, that are accretive to shareholder value
    • The Company, together with Anchorage Digital and Kamino, launched the first-ever digital asset treasury to enable borrowing against natively staked SOL in qualified custody
    • Initiated a strategic roadmap to invest in a new low-latency cluster in Asia Pacific to drive staking and validation



    "The Company's business expansion through the implementation of the DAT strategy has delivered tangible results. The Company maintains a strengthened balance sheet, and sufficient liquidity to support ongoing investment activities and long-term sustainable growth." Joseph Chee, Executive Chairman at Solana Company said. "Notwithstanding the foregoing, the unanticipated and adverse downturn in the cryptocurrency industry—which we believe has been exacerbated by geopolitical uncertainties including U.S. tariff policies, armed conflicts and elevated crude oil prices—has adversely impacted the performance of the DAT strategy. Nevertheless, the Company remains steadfast in its long-term SOL accumulation strategy, with a particular focus on enhancing SOL per share metrics and expanding its SOL holdings in an accretive fashion. The Company's objective of serving as the institutional access gateway for exposure to the Solana Ecosystem remains unchanged and firmly intact."

    Cosmo Jiang, General Partner at Pantera Capital and board director at Solana Company said, "Consistent with our recent announcement of the first-of-its-kind institutional-grade yield enhancement solution in collaboration with Kamino and Anchorage, together with business development initiatives aimed at revenue diversification such as the Pacific Backbone project, the Company plans to continue to pursue the generation of incremental cash flows for Solana Company in a safe and compliant manner. The Company also intends to pursue highly selective strategic capital markets transactions to advance the achievement of its stated objectives."

    Fourth Quarter 2025 Financial Results

    Fourth quarter revenue was $5.2 million, compared to $0.2 million in the prior-year period, driven by $5.1 million in staking rewards.

    For the fourth quarter, cost of revenue was $0.2 million, in line with the prior-year period.

    Selling, general and administrative expenses for the fourth quarter of 2025 were $13.0 million, compared to $2.2 million in the prior-year period, due primarily to increased non-cash compensation costs, salaries and wages, digital asset management and custodian fees as well as legal and professional fees in conjunction with the addition of the Company's DAT strategy. Research and development expenses were $0.9 million, in line with the prior-year period.

    Total operating expenses for the fourth quarter of 2025 were $206.1 million, compared to $3.1 million in the prior-year period. Operating expenses also included non-cash charges of $178.3 million for unrealized loss on digital assets and digital assets receivable, $12.1 million for realized loss on digital assets, and $2.1 million for unrealized loss on digital assets fund investment, due to the decline in the value of SOL.

    The resulting loss from operations was $201.1 million compared to a loss of $3.1 million for the prior-year period.

    Non-operating income in the fourth quarter of 2025 was $526.6 million, primarily driven by a $526.3 million gain from the change in fair value of derivative liability compared to non-operating loss of $0.8 million for the prior year period comprised mostly of foreign exchange loss.

    Reported net income for the fourth quarter of 2025 was $325.6 million, or earnings of $4.25 per basic and diluted common share, compared to a net loss of $3.9 million, or a loss of $793.01 per basic and diluted common share, in the prior-year period.

    Full Year 2025 Financial Results

    Full year 2025 revenue was $6.0 million, compared to $0.5 million in the prior year, primarily reflecting $5.5 million in staking rewards earned following the launch of the Company's DAT strategy in September 2025.

    Cost of revenue for the full year was $0.5 million, compared to $0.6 million in the prior year. Gross profit was $5.5 million compared to a gross loss of $0.1 million in the prior year.

    Selling, general and administrative expenses for the full year were $23.1 million, compared to $10.2 million in the prior year, due primarily to the increases in the fourth quarter noted above. Research and development expenses were $3.5 million, relatively flat compared to $3.7 million in the prior year.

    Full year operating expenses also included the same non-cash digital asset charges noted above, resulting in total operating expenses of $249.4 million compared to $13.8 million in the prior year. Loss from operations was $243.8 million compared to a loss of $13.9 million in the prior year.

    Non-operating income for the full year was $203.0 million, primarily driven by the elimination of the derivative liability through the amendment of the terms of the statutory warrants, partially offset by financing costs.

    Net loss for the full year 2025 was $40.9 million, or a loss of $1.85 per basic and diluted common share, compared to a net loss of $11.7 million, or a loss of $3,282.26 per basic and diluted common share, in the prior year.

    Cash and Liquidity

    At December 31, 2025, cash totaled $7.3 million and digital assets at fair value totaled $293.7 million, for a combined total of $301.0 million. Also at that date, common shares issued and outstanding totaled 43.7 million, along with an additional 40.4 million shares comprised of in-the-money warrants, all totaling 84.1 million shares. At March 27, 2026, common shares outstanding totaled 55.0 million, net of repurchased shares year-to-date held in treasury, along with in-the-money warrants of 27.6 million, reflecting the exercise of pre-funded warrants during the first quarter of 2026, for a total of 82.6 million.

    Conference Call

    Management will host a conference call to discuss the results and provide an expanded business update as follows:

    Date:Monday, March 30, 2026
    Time:4:30 p.m. Eastern Time
    Webcast:Click here
    Participant call link:Click here (register to receive unique PIN and dial-in number)
    The webcast will be archived under the News & Events section of the Company's investor relations website.
     
     

    About Solana Company

    Solana Company (NASDAQ:HSDT) is a listed digital asset treasury dedicated to acquiring Solana (SOL), created in partnership with Pantera and Summer Capital. Focused on maximizing SOL per share by leveraging capital markets opportunities and on-chain activity, Solana Company offers public market investors optimal exposure to Solana's secular growth. https://www.solanacompany.co/

    For additional information, follow us on:

    https://x.com/Solana_Company

    https://www.linkedin.com/company/helius-solana-company/

    Forward Looking Statements

    This press release contains statements that constitute "forward-looking statements" within the meaning of the U.S. federal securities laws. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms or other comparable terminology. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Forward-looking statements may include, among others, statements in relation to the expected benefits and implementation of the Company's digital asset treasury strategy; expected staking, yield and broader opportunities across the Solana ecosystem; the Company's expected treasury growth; the Company's future growth and operational progress; the impacts of the current global macroeconomic environment on the Company, and the sufficiency of the Company's cash and availability of funds and operating costs.

    These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors-many of which are beyond the Company's control-that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, capital requirements to achieve the Company's business objectives; expected benefits and implementation of the Company's digital asset treasury strategy, expected staking, yield and broader opportunities across the Solana ecosystem; the Company's expected token treasury growth, the impact on the Company of global macroeconomic conditions including effects from supply chain constraints, including risks related to manufacturing delays, logistics challenges, labor shortages, disruptions in the banking system and financial markets; high levels of inflation and high interest rates on the Company's ability to operate its business and access capital markets; the success of the Company's business plan; the Company's operating costs and use of cash; the Company's ability to achieve significant revenues; and other risks and uncertainties described under "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and in other subsequent filings with the SEC, including its upcoming Annual Report on Form 10-K for the year ended December 31, 2025, and in other subsequent filings with the SEC. These filings are available at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

    Media Contacts:

    Solana Company

    [email protected]

    Pantera Capital Management LP

    [email protected]

    [email protected]

    Summer Capital Limited

    [email protected]

     
    Solana Company

    Unaudited Consolidated Balance Sheets

    (in thousands, except share data)

       
     December 31, 2025    December 31, 2024
    ASSETS      
    Current assets      
    Cash and cash equivalents$7,282  $1,088 
    Digital assets 21,000   — 
    Inventory 1,121   1,036 
    Prepaid expenses and other current assets 1,752   1,300 
    Total current assets 31,155   3,424 
    Digital assets 196,724  — 
    Digital assets, restricted 39,219  — 
    Digital assets receivable 31,139  — 
    Digital assets fund investment 5,617  — 
    Other long-term assets 75  118 
    Total assets$303,929  $3,542 
    LIABILITIES AND STOCKHOLDERS' EQUITY       
    Current liabilities       
    Accounts payable$1,890  $873 
    Accrued and other current liabilities 1,126   1,290 
    Total current liabilities 3,016   2,163 
    Other long-term liabilities —   79 
    Derivative liability —  241 
    Total liabilities 3,016   2,483 
    Stockholders' equity       
    Class A common stock, $0.001 par value; 800,000,000 shares authorized; 43,744,207 and 4,936 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively 44   — 
    Additional paid-in capital 513,719   172,425 
    Accumulated deficit (212,589)  (171,699)
    Accumulated other comprehensive (loss) income (261)  333 
    Total stockholders' equity 300,913   1,059 
    Total liabilities and stockholders' equity$303,929  $3,542 
            



            
    Solana Company

    Unaudited Consolidated Statements of Operations

    (in thousands, except share and per share data)

         
     Three Months Ended Years Ended
     December 31, December 31,
     2025  2024  2025  2024 
    Revenue      
    Staking revenue$5,127  $—  $5,469  $— 
    Product sales and other revenue 101  152   548  520 
    Total revenue 5,228  152   6,017  520 
    Cost of revenue 180  154   500  582 
    Gross profit (loss) 5,048   (2)  5,517   (62)
    Operating expenses      
    Selling, general and administrative expenses 13,038  2,219   23,127   10,182 
    Research and development expenses 886  924   3,511   3,659 
    Unrealized loss on digital assets and digital assets receivable 178,315  —  208,855  — 
    Realized loss on digital assets 12,127  —  12,127  — 
    Unrealized loss on digital assets fund investment 2,053  —  2,053  — 
    Realized gain on digital asset derivatives (316) —  (316) — 
    Total operating expenses 206,103  3,143   249,357   13,841 
    Loss from operations (201,055)  (3,145)  (243,840)  (13,903)
    Nonoperating income      
    Interest expense, net —  (3) (635) (17)
    Change in fair value of derivative liability 520,324   (46)  937,718  2,981 
    Foreign exchange gain (loss) and other income 282   (733)  785  (803)
    Loss on derivative liability 6,000  —  (539,733) — 
    Financing costs —   —   (195,185) — 
    Nonoperating income, net 526,606   (782)  202,950   2,161 
    Income (loss) before provision for income taxes 325,551  (3,927) (40,890) (11,742)
    Provision for income taxes —  —  —  — 
    Net income (loss)$325,551  $(3,927) $(40,890) $(11,742)
    Earnings (loss) per share      
    Basic and diluted$4.25  $(793.01) $(1.85) $(3,282.26)
    Weighted average number of common shares outstanding     
    Basic and diluted 76,614,643   4,952   22,047,841   3,577 
                    


    Primary Logo

    Get the next $HSDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026

    NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its fourth quarter and full year operating results on Monday, March 30, 2026, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Monday, March 30, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived unde

    3/24/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana

    Deployment to be focused on Asia-Pacific region to capitalize on fast-growing wealth accumulation, cross-border payments, and institutional adoption of digital assetsExpansion planned to enable Solana Company to capture more value by eliminating external costs and providing compliant infrastructure for regulated institutionsStrategic buildout designed to address needs of market makers, high-frequency traders, exchanges, and traditional finance partners across the Solana ecosystem NEWTOWN, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT or the "Company") today rolled out a strategic roadmap to invest in a new low-latency cluster in Asia Pacific to drive staking and v

    2/23/26 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    SEC Filings

    View All

    SEC Form POSASR filed by Solana Company

    POSASR - Solana Co (0001610853) (Filer)

    3/30/26 6:11:17 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form POSASR filed by Solana Company

    POSASR - Solana Co (0001610853) (Filer)

    3/30/26 5:54:37 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company filed SEC Form 8-K: Other Events

    8-K - Solana Co (0001610853) (Filer)

    2/20/26 5:07:27 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jiang Cosmo Yi

    3 - Solana Co (0001610853) (Issuer)

    10/31/25 6:51:45 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Chee Choon Wee claimed ownership of 6,830,402 shares (SEC Form 3)

    3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    9/25/25 5:00:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    7/3/25 8:00:26 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Noble Capital Markets initiated coverage on Helius Medical with a new price target

    Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

    3/24/21 8:02:45 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

    LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

    2/12/21 8:21:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

    NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

    5/20/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026

    NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its fourth quarter and full year operating results on Monday, March 30, 2026, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Monday, March 30, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived unde

    3/24/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Reports Third Quarter 2025 Financial Results

    NEWTOWN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter ended September 30, 2025. Third Quarter and Recent Business Updates Closed partnership with Pantera Capital and Summer Capital of over $500 Million in funding in cash and stablecoins to launch SOL treasury strategyIssued cash-exercise warrants, allowing for a potential aggregate $750M additional capital raise for the CompanyLaunched ATM program, giving the company flexibility to raise addi

    11/18/25 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care